ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
38.82
-0.49%
US Tech 100
18,944.80
0.43%
S&P 500
5,572.07
-0.76%
US Dollar vs CAD
1.44578
0.17%
Bitcoin
82,438.61
-0.49%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Zevra Therapeutics Inc (ZVRA) Share Price

Zevra Therapeutics Inc

Zevra Therapeutics Inc (ZVRA)

NASDAQ
8.07
0.07
(0.88%)
Closed March 11 3:00PM
Delayed by 15 minutes
8.07
0.00
( 0.00% )
Pre Market: 3:00AM
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
8.07
Bid
7.72
Ask
8.16
Volume
-
0.00 Day's Range 0.00
4.20 52 Week Range 9.76
Market Cap
430.744M
Previous Close
8.07
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
431,397
Shares Outstanding
53,375,932
Dividend Yield
-
PE Ratio
-6.73
Earnings Per Share (EPS)
-0.86
Revenue
27.46M
Net Profit
-46.05M

About Zevra Therapeutics Inc

Zevra Therapeutics, Inc. is a rare disease therapeutics company. The Company is engaged in creating therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical-stage pipeline and ... Zevra Therapeutics, Inc. is a rare disease therapeutics company. The Company is engaged in creating therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical-stage pipeline and commercial stage assets. It employs its LAT platform technology to create a portfolio of approved products. Its product candidates include Arimoclomol, KP1077IH, KP1077N and AZSTARYS. Arimoclomol is an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate, which is being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (SDX), the Company's prodrug of d-methylphenidate (d-MPH). AZSTARYS is a prodrug for the treatment of ADHD in patients aged six years or older. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.kempharm.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Zevra Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ZVRA. The last closing price for Zevra Therapeutics was US$8.07. Over the last year, Zevra Therapeutics shares have traded in a share price range of US$ 4.20 to US$ 9.76.

Zevra Therapeutics currently has 53,375,932 shares outstanding. The market capitalization of Zevra Therapeutics is US$430.74 million. Zevra Therapeutics has a price to earnings ratio (PE ratio) of -6.73.

Ask ADVFN Intelligence (AI)

ZVRA Latest News

More News

Form 8-K - Current report
Edgar (US Regulatory)
12 hours ago
ZVRA (0.88%)

Form 8-K - Current report
Edgar (US Regulatory)
February 27 2025
ZVRA (0.88%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 14 2025
ZVRA (0.88%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 14 2025
ZVRA (0.88%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
February 14 2025
ZVRA (0.88%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.6558.833445718147.4158.25917.334656978.01160294CS
40.618.176943699737.468.25917.213789117.80358528CS
12-0.42-4.946996466438.498.957.214313978.07184239CS
260.243.065134099627.839.766.616416518.16119639CS
521.6425.50544323486.439.764.25659087.36222951CS
1562.4242.83185840715.659.763.893976336.75636421CS
2602.4242.83185840715.659.763.893976336.75636421CS

ZVRA - Frequently Asked Questions (FAQ)

What is the current Zevra Therapeutics share price?
The current share price of Zevra Therapeutics is US$ 8.07
How many Zevra Therapeutics shares are in issue?
Zevra Therapeutics has 53,375,932 shares in issue
What is the market cap of Zevra Therapeutics?
The market capitalisation of Zevra Therapeutics is USD 430.74M
What is the 1 year trading range for Zevra Therapeutics share price?
Zevra Therapeutics has traded in the range of US$ 4.20 to US$ 9.76 during the past year
What is the PE ratio of Zevra Therapeutics?
The price to earnings ratio of Zevra Therapeutics is -6.73
What is the cash to sales ratio of Zevra Therapeutics?
The cash to sales ratio of Zevra Therapeutics is 11.29
What is the reporting currency for Zevra Therapeutics?
Zevra Therapeutics reports financial results in USD
What is the latest annual turnover for Zevra Therapeutics?
The latest annual turnover of Zevra Therapeutics is USD 27.46M
What is the latest annual profit for Zevra Therapeutics?
The latest annual profit of Zevra Therapeutics is USD -46.05M
What is the registered address of Zevra Therapeutics?
The registered address for Zevra Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Zevra Therapeutics website address?
The website address for Zevra Therapeutics is www.kempharm.com
Which industry sector does Zevra Therapeutics operate in?
Zevra Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
HCTIHealthcare Triangle Inc
US$ 0.5237
(61.14%)
2.26M
PALIPalisade Bio Inc
US$ 1.38
(46.81%)
603.3k
SSPEW Scripps Company
US$ 1.94
(35.66%)
297.26k
VCIGVCI Global Ltd
US$ 0.784
(28.50%)
2
HSCSHeartSciences Inc
US$ 3.56
(21.92%)
3
HEPAHepion Pharmaceuticals Inc
US$ 0.0534
(-36.43%)
806.51k
SYRSSyros Pharmaceuticals Inc
US$ 0.0931
(-31.54%)
355.71k
SKKSKK Holdings Limited
US$ 0.60
(-30.15%)
978
ZYXIZynex Inc
US$ 5.25
(-25.00%)
1.45k
TNONTenon Medical Inc
US$ 1.18
(-21.85%)
25.39k
HCTIHealthcare Triangle Inc
US$ 0.5237
(61.14%)
2.26M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
US$ 8.31
(5.06%)
1.39M
HEPAHepion Pharmaceuticals Inc
US$ 0.0534
(-36.43%)
806.51k
SHViShares Short Treasury Bond ETF
US$ 110.235
(0.01%)
650.84k
PALIPalisade Bio Inc
US$ 1.38
(46.81%)
603.3k

Discussion

View Full Feed
igotthemojo igotthemojo 7 minutes ago
Lam Dong intends to purchase Kblb spider silk for 20 bil dong and will export it somewhere?…
KBLB
236T568 236T568 12 minutes ago
Breaking news: The EU has retaliated against Donald Trump’s 25% metals tariffs with measures affecting up to €26bn of US goods

https://bsky.app/profile/financialtimes.com/post/3lk5vt76obc2o
DarthYoda DarthYoda 17 minutes ago
Go git em Granny..."Grandma Posse’ making sure every Bitcoin ATM in Omaha has scam warning sticker":
3/11/2025
https://www.msn.com/en-us/crime/general/grandma-posse-making-sure-every-bitcoin-atm-in-omaha-has-scam-warning-sticker/ar-AA1AEGI9
BTCUSD
joeycav11 joeycav11 21 minutes ago
Hoping Britain wants to regain some of its previous greatness by announcing first approval of the new cutting edge treatment showing efficacy and minimal side effects
On the financial front I hope they announce there subsidizing the cost to its citizens by charging full price to offshore pa
NWBO
joeycav11 joeycav11 21 minutes ago
Hoping Britain wants to regain some of its previous greatness by announcing first approval of the new cutting edge treatment showing efficacy and minimal side effects
On the financial front I hope they announce there subsidizing the cost to its citizens by charging full price to offshore pa
NWBO
JusDePomme JusDePomme 24 minutes ago
Agree with u Richie!
funnytimes2 funnytimes2 26 minutes ago
On February 13, the Department of Finance of Lam Dong province informed that since the beginning of 2025, the whole province has attracted 2 projects with non-budgetary capital, with a registered capital of 1,304 billion VND. Of which, the project to purchase silk fibers for export from Kraig Biocra
KBLB
Bubae Bubae 27 minutes ago
Look at you denigrating someone about due diligence while simply parroting the company's press releases. 😆 That isn't due diligence. I always like when a company boasts about revenue without the context of a balance sheet or at lease an EBITDA number that may reveal the cost associated with
ASII
trunkmonk trunkmonk 41 minutes ago
Surprisingly they are everywhere, they miss every run, come in afterwards, spend all their time posting while waiting to get in on simple wave patterns, or they simply stalk the price down pretending it’s their doing. One thing is clear, u rarely if ever make money from their advice, and their messa
XRPUSD
Bigstud is here Bigstud is here 48 minutes ago
So if a person own 58 shrs before split and then have a 1 for 60 RS. How many shrs does a person get? Or do they pay Cash In Lieu. instead of giving shrs.
MULN
DarthYoda DarthYoda 52 minutes ago
"That doesn't happen by being a scam" you say?
BBBut..."Cryptocurrency fraud is now the riskiest scam for consumers, according to BBB":
March 6, 2024
https://www.cbsnews.com/news/crypto-scam-risk-bbb-report/
"Crypto Scams Cost Investors Over $10 Billion in 2024":
M
XRPUSD
RichieBoy RichieBoy 60 minutes ago
Probably why LinkedIn bothers me as much as it does. Abhorrent navigation, it's like running a marathon in a gigantic corn maze. Anyways click the link I gave you, then scroll down until you see something like (See these 17 jobs).

Livo appears to be a massive job listing service (at l
AFFU
PC retired PC retired 1 hour ago
I don't read it that way. It seems to me that the defense team asked for and were granted permission to withdraw from the case, presumably because they have not been paid and the eviction order has been set aside to allow a new defense team to be employed. The state of affairs that led to the evicti
ASRE
rbtree rbtree 1 hour ago
WTF would you post that FE nonsense here?
LUNR
satter satter 1 hour ago
https://youtu.be/-NI6T9EjBtY?si=SVN2A6T6vNTdazJi


And yet this one was put out just 6 hrs ago, 2 days after the other one from the same Dream 4 Coins.

It says nothing about the so called Rnva acquisition of Foxo. It describes what appears to be a neutral balanced
RNVA
ombowstring ombowstring 1 hour ago
Historic videos -

https://www.youtube.com/@NASS_0
88TH MAN 88TH MAN 2 hours ago
Assuming they file current, the change will be automatic.
FBEC
$2.00 or no deal $2.00 or no deal 2 hours ago
***** NEW *****

PURDUE PHARMA L.P. et al v ELITE LABORATORIES INC, et al.

https://www.pacermonitor.com/case/51356241/PURDUE_PHARMA_LP_et_al_v_ELITE_LABORATORIES_INC,_et_al

Tuesday, March 11, 2025
ELTP
ombowstring ombowstring 2 hours ago
US now hated around the world -

https://www.theguardian.com/us-news/2025/mar/12/i-feel-utter-anger-from-canada-to-europe-a-movement-to-boycott-us-goods-is-spreading
Controlledoilandgas Controlledoilandgas 2 hours ago
It's an Etrade account, we've tried to locate the individual with no luck. 

Financial report is scheduled to release at 6:10 AM EST / 5:10 AM Central.

Press release should start hitting the main wires at the same time. 
AZRH
DarthYoda DarthYoda 2 hours ago
The higher a market cap, the more likely it is over valued, which is why this list of overvalued stocks is defined by high market caps...where do the market caps of your various "coins" fit into this list? Do your "coins" produce or provide anything as useful as the goods or services provided by any
XRPUSD
littlejohn littlejohn 2 hours ago
No depression, yes, a wind storm shut down

I-10 in Arizona a day before the market

had it's first big down day recently...

Ok, enough weather geek chat...

Transitory is a Great term to use for

things going on now...
pgsd pgsd 2 hours ago
"Our priority regulatory pathways to support innovation and the introduction of new medical products will be described in our Science Strategy and align with the following areas":

Vaccines and immunotherapies
Biotherapeutics, cell and gene therapies
Diagnostics and genom
NWBO
Zorax Zorax 2 hours ago
I'm sorry but that read like a Andy Borowitz report.

Your Recent History

NASDAQ
ZVRA
Zevra Therapeutics
TG
IXD1
Industria De Diseno Textil
BOV
IBLV
Ibovespa Smart Low Volat...
TG
A28WV5
Schlumberger Finance NV
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads